Life Recovery Systems Receives CE Approval For ThermoSuit System
Life Recovery Systems's ThermoSuit System has been granted European CE Mark (Conformite Europeene) approval for Temperature reduction in patients where clinically indicated, e.g., to induce hypothermia in patients to preserve cardiac and brain function in victims of cardiac arrest, stroke, heart attack, traumatic brain injury and hyperthermic patients.
The ThermoSuit System uses innovative technology to rapidly cool a patient's core temperature. It consists of a disposable body suit and a means to pump coolant within the suit over the skin of the patient. It is the first device for patient temperature management that conveniently provides a thin layer of rapidly flowing liquid coolant in direct contact with the skin. This approach gives the ThermoSuit System outstanding capabilities to rapidly and non-invasively change patient temperature. It has been designed for ease of use for clinicians who treat patients indicated for cooling therapy, and has the potential to quickly cool these patients conveniently and rapidly.
"European CE Mark approval of the ThermoSuit System is an important next step in achieving our company's mission," said John DiLiddo, Life Recovery Systems' Vice President of Marketing and Sales. "With the introduction in Europe of the ThermoSuit System for use in the hospital, physicians and nurses will now have a convenient, easy-to-use tool in the delivery of emergency hypothermia therapy."
Evolving International standards of care recommend that "unconscious adult patients with spontaneous circulation after out-of-hospital cardiac arrest should be cooled to 32 degrees C to 34 degrees C for 12-24 hours when the initial rhythm was ventricular fibrillation. Such cooling may also be beneficial for other rhythms or in-hospital cardiac arrest."